Ipsen

Ipsen FCF/Debt

The Free Cash Flow to Debt Ratio of Ipsen (IPN.PA) as of Oct 10, 2026 is 131.86 %. In the previous year, Free Cash Flow to Debt Ratio was 31.15 % — a change of 323.33% (higher).

FCF/Debt

131.86 %

YoY

323.33%

Last updated:

Free Cash Flow to Debt Ratio of Ipsen is 2025 131.86 % . Free Cash Flow to Debt Ratio of Ipsen was 2024 31.15 % . It decreases by 323.33% higher compared to the previous year.

The Ipsen FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
138.56 EUR
Jan 1, 2019
34.26 EUR
Jan 1, 2020
72.42 EUR
Jan 1, 2021
69.47 EUR
Jan 1, 2022
103.34 EUR
Jan 1, 2023
157.67 EUR
Jan 1, 2024
31.15 EUR
Jan 1, 2025
131.86 EUR
The Ipsen FCF/Debt history
YEARFCF/DebtYoY
131.86 %+323.33%
31.15 %-80.24%
157.67 %+52.57%
103.34 %+48.75%
69.47 %-4.07%
72.42 %+111.39%
34.26 %-75.28%
138.56 %+48.30%
93.43 %+20.03%
77.84 %-92.79%
1,079.50 %-45.57%
1,983.17 %—
Access this data via the Eulerpool API

Ipsen Stock analysis

What does Ipsen do? Ipsen SA is a French biopharmaceutical company specialized in the development of drugs for the treatment of cancer, neurological disorders, and endocrine disorders. It was founded in 1929 by a pharmacist named Henri Beaufour and is headquartered in Paris. The history of Ipsen began with the production of extraction products from snake venom for the manufacturing of serum against tetanus and diphtheria. In the 1960s, the company started to focus on the production of hormones and peptides, with a focus on endocrine disorders. In the 1990s, Ipsen expanded its product portfolio to include oncology and neurological disorders. Ipsen's business model focuses on research and development of new drugs, as well as marketing of already established drugs in selected markets worldwide. The company employs around 5,700 employees and operates in more than 115 countries. Ipsen has two main business segments: specialty drugs and consumer healthcare. The specialty drugs segment focuses on the development and marketing of innovative therapies in the areas of oncology, endocrinology, and neuroscience. Ipsen's most well-known products include Somatuline, a drug for the treatment of acromegaly, and Decapeptyl, a drug for the treatment of prostate cancer and endometriosis. In the consumer healthcare segment, Ipsen is mainly specialized in the production of drugs for the treatment of gastrointestinal disorders and cold and flu symptoms. Some well-known brands include Smecta, a drug for diarrhea, and Nurofen, a pain reliever. Ipsen also has a strong presence in the field of aesthetic medicine, where the company operates a subsidiary called Ipsen Aesthetic. This subsidiary develops and markets products for the treatment of wrinkles and other signs of aging on the skin. Well-known brands of Ipsen Aesthetic include Dysport, a botulinum toxin product for the treatment of wrinkles, and the filler Restylane. Overall, Ipsen has established itself as a leading biopharmaceutical company focused on the development and marketing of products in specialized therapy areas. The company has a strong pipeline of new products in development and remains an important player in the pharmaceutical industry due to its strong scientific expertise and global presence. Ipsen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ipsen stock

Free Cash Flow to Debt Ratio of Ipsen is 131.86 % in 2025.

Free Cash Flow to Debt Ratio of Ipsen changed from 31.15 % to 131.86 %, representing a 323.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Ipsen since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Ipsen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Ipsen

All Key Metrics — Ipsen